Flash Finance

Innova Captab LimitedINNOVACAPCorporate

Pharmaceuticals - Indian - Bulk Drugs & Formln Latest results: Jun 2026 14 quarters of data
Consolidated Standalone
₹1,019.80
MCap ₹5,836 Cr · P/E 61.1
Innova Captab Limited — Stock analysis & AI research Innova Captab Limited — Multibagger AI analysis Innova Captab Limited — Seasonality — best & worst months Innova Captab Limited — Technical indicators & charts Innova Captab Limited — Technical setup — score, trend, support & resistance Innova Captab Limited — Live exchange announcements
📋 High ROE Stocks📋 High Interest Coverage Stocks📋 Low P/E Stocks📋 Stocks Cheaper Than Their Industry📋 High Profit Growth Stocks📋 Stocks With Strong Quarterly Results 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹400 Cr
Sales · Jun 2026
+39.5% YoY
₹54 Cr
Operating Profit · Jun 2026
+55.2% YoY
13.5%
OPM % · Jun 2026
+11.6% YoY
₹32 Cr
Net Profit · Jun 2026
+58.0% YoY
₹5.60
EPS · Jun 2026
+57.7% YoY

📝 Innova Captab Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Innova Captab Limited reported revenue of ₹400 crore for the quarter ended June 2026 (Q1 FY27), up 39.5% from ₹287 crore in the same quarter last year, and up 11.8% sequentially over the March 2026 quarter.

Net profit rose 58.0% year-on-year to ₹32 crore, from ₹20 crore. Earnings per share (EPS) came in at ₹5.60.

Operating profit stood at ₹54 crore — an operating margin (OPM) of 13.5%, compared with 12.1% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Innova Captab Limited posted revenue of ₹1,299 crore, a decline of 58.6% over FY25, with a net profit of ₹84 crore (down 65.6% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹1,412 crore with a net profit of ₹95 crore.

Valuation snapshot

At the current price of ₹1,019.80, INNOVACAP has a market capitalisation of ₹5,836 crore and a trailing P/E of about 61.1.

Within the Pharmaceuticals - Indian - Bulk Drugs & Formln industry, it is the 6th-largest of the 47 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 50.90%, foreign institutional investors (FIIs) 0.84%, domestic institutional investors (DIIs) 19.16%, public shareholders 29.09% of Innova Captab Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹5,836 Cr
Current Price ?
₹1,019.8
P/E ?
61.14above ind
Industry P/E ?
37.20
P/B ?
6.59
P/S ?
4.13
P/FCF ?
-208.42
Enterprise Value ?
₹6,157 Cr
EV/EBITDA ?
36.43
PEG ?
4.37
Earnings Yield ?
2.1%
Dividend Yield ?
0.20%
Profitability & Returns
Sales (TTM) ?
₹1,412 Cr
OPM ?
12.0%
Profit after tax (TTM) ?
₹95 Cr
EPS (TTM) ?
₹16.68
ROCE ?
11.0%
ROE ?
10.8%
ROA ?
6.2%
Growth
Sales — latest qtr ?
₹400 Cr
PAT — latest qtr ?
₹32 Cr
YoY qtr sales growth ?
39.5%
YoY qtr profit growth ?
58.0%
Sales growth (3y) ?
15%
Sales growth (5y) ?
26%
Profit growth (3y) ?
14%
Profit growth (5y) ?
19%
Financial Health
Debt ?
₹321 Cr
Debt to Equity ?
0.36
Interest Coverage ?
7.3
Current Ratio ?
N/A
Ownership
Promoter holding ?
50.90%
Change in promoter holding ?
0.00%
Pledged percentage ?
N/A
Market
Return 3 months ?
5.9%
Return 6 months ?
37.4%

🗓️ Quarterly results (14 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 2172192122361982272402492,425287290364358400 +39.5% +11.8%
Operating Profit 22282631232833322823529473954 +55.2% +39.9%
Other Income 212265434445333 -37.4% +0.8%
Interest 545400001935344 +45.7% +1.3%
Depreciation 3333333378999910 +6.7% +3.0%
Profit Before Tax 16212026263034332292719372843 +57.7% +54.1%
Net Profit 14151419202226241712014282132 +58.0% +51.5%
EPS 2.813.193.013.263.453.904.484.262.993.552.504.883.705.60 +57.7% +51.4%
OPM % 10.1% 12.8% 12.3% 12.9% 11.8% 12.5% 13.8% 13.1% 11.6% 12.1% 10.1% 12.9% 10.8% 13.5% +11.6% +25.0%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹3,141 Cr ₹1,299 Cr ₹1,412 Cr -58.6%
Operating Profit ₹376 Cr ₹150 Cr ₹169 Cr -60.2%
OPM % 11.97% 11.53% 11.97% -3.7%
NPM % 7.76% 6.44% 6.76% -17.0%
Other Income ₹56 Cr ₹15 Cr ₹13 Cr -73.5%
Depreciation ₹87 Cr ₹37 Cr ₹38 Cr -57.2%
Interest ₹19 Cr ₹15 Cr ₹17 Cr -18.8%
EBIT ₹289 Cr ₹112 Cr ₹131 Cr -61.0%
PBT ₹326 Cr ₹112 Cr ₹128 Cr -65.7%
Tax ₹82 Cr ₹28 Cr ₹32 Cr -65.7%
Net Profit ₹244 Cr ₹84 Cr ₹95 Cr -65.6%
EPS ₹15.63 ₹14.63 ₹16.68 -6.4%
Material Cost ₹2,405 Cr ₹939 Cr ₹1,021 Cr -60.9%
Employee Cost ₹255 Cr ₹111 Cr ₹116 Cr -56.4%
Extraordinary Items — — — —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 48575757 +0.0%
Reserves 220666756829 +9.7%
Borrowings 237244329321 -2.4%
Other Liabilities 173187223339 +52.0%
Total Liabilities 6781,1551,3651,547 +13.3%
Fixed Assets 161164637648 +1.7%
CWIP 223392115 -28.6%
Investments 606060101 +68.3%
Other Assets 435593647782 +20.9%
Total Assets 6781,1551,3651,547 +13.3%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 391122034 +70.0%
Cash from Investing Activity -88-472-100-14 +86.0%
Cash from Financing Activity 5136884-34 -140.5%
Net Cash Flow 384-14 -450.0%
Free Cash Flow -39-165-141-28 +80.1%
CFO/OP 59%123%32%36% +12.5%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 98929593 -2.1%
Inventory Days 676894103 +9.6%
Days Payable 102111119145 +21.8%
Cash Conversion Cycle 63497051 -27.1%
Working Capital Days 44586582 +26.2%
ROCE % 21%15%12%11% -8.3%

👥 Shareholding (latest 5 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Sep 2026 % Chg
Promoters 50.90%50.90%50.90%50.90%50.90% +0.0%
FIIs 0.23%0.08%0.10%0.23%0.84% +265.2%
DIIs 19.67%20.17%20.24%20.14%19.16% -4.9%
Public 29.20%28.86%28.76%28.74%29.09% +1.2%
No. of Shareholders 41,01440,24538,69136,96536,551 -1.1%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln · top 25 of 47 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 AKUMS Akums Drugs ₹784.55 12,012 41.2 4,502 293 12.6% 6.5% 5.9% -25.5% 13.9% 56.1%
2 STAR Strides Pharma ₹1,085.00 10,001 26.7 3,636 389 25.4% 10.7% -20.4% 99.0% 11.2% 50.0%
3 BLUEJET Blue Jet ₹565.05 9,802 36.9 884 265 36.3% 30.0% 8.0% 0.7% -17.5% -14.3%
4 AARTIPHARM Aarti Pharmalabs ₹828.30 7,511 36.1 1,957 208 22.0% 10.6% 1.5% -26.9% 42.4% 39.2%
5 SUPRIYA Supriya Lifescience ₹870.30 7,004 35.3 873 198 33.2% 22.7% 18.9% 11.1% 30.8% -30.9%
6 INNOVACAP Innova Captab ₹1,199.30 6,863 13.8 5,779 497 14.6% 8.6% 355.1% 277.4% 33.9% 42.3%
7 MOREPENLAB Morepen Laboratories ₹123.35 6,759 48.0 1,951 141 9.4% 7.2% -0.3% -18.3% 34.1% 394.0%
8 IOLCP IOL Chemicals ₹201.19 5,905 35.2 2,523 168 12.3% 6.7% 11.5% 36.6% 37.1% 89.8%
9 FDC FDC ₹350.20 5,702 19.5 2,191 291 15.3% 13.3% 3.0% 4.8% 3.0% 9.5%
10 NOVARTIND Novartis India ₹2,257.80 5,575 57.0 371 97 27.6% 26.2% -0.3% -6.9% 18.2% 14.3%
11 ORCHPHARMA Orchid Pharma ₹1,058.75 5,370 236.9 812 22 5.1% 2.7% -11.9% -76.4% 0.2% 25.4%
12 RPGLIFE RPG Life ₹2,865.90 4,740 39.7 735 120 21.1% 16.3% 8.4% -36.9% 15.8% 16.3%
13 ZOTA Zota Health ₹1,232.70 4,269 — 609 -104 0.6% -17.1% 84.6% -29.8% 66.9% -213.9%
14 GUFICBIO Gufic Biosciences ₹419.85 4,210 57.3 974 74 16.9% 7.6% 14.7% -9.1% 14.9% 86.0%
15 UNICHEMLAB Unichem Laboratories ₹526.70 3,708 12.2 2,308 305 9.9% 13.2% 6.2% 74.1% 20.1% 496.1%
16 INDSWFTLAB Ind-Swift Laboratories ₹374.00 3,252 55.4 665 57 9.0% 8.6% 235.3% 10.1% 32.3% -88.7%
17 ADVENZYMES Advanced Enzyme ₹293.25 3,249 19.8 750 172 29.8% 22.9% 17.1% 29.6% 2.1% -4.6%
18 SOLARA Solara Active ₹667.00 3,218 85.6 1,535 37 15.2% 2.4% 6.6% -1470.4% 33.1% 381.8%
19 DCAL Dishman Carbogen ₹162.08 2,541 157.6 2,902 16 16.7% 0.6% 8.1% 2655.7% -4.3% -351.7%
20 INDOCO Indoco Remedies ₹254.59 2,347 n/m 1,872 3 8.8% 0.2% 10.7% -26.5% 6.5% 280.0%
21 PANACEABIO Panacea Biotec ₹368.55 2,257 — 673 -9 0.3% -1.3% 14.4% 17.9% 19.7% -44.4%
22 REMUS Remus Pharma. ₹1,911.30 2,252 91.1 94 25 31.7% 26.7% — — 13.3% 21.4%
23 SAKAR Sakar Healthcare ₹987.40 2,167 61.0 272 36 28.5% 13.3% 41.9% 71.8% 38.4% 120.2%
24 JAGSNPHARM Jagsonpal Pharmaceuticals ₹227.53 1,501 33.3 294 45 20.7% 15.4% 6.9% -22.2% 8.5% 20.4%
25 KOPRAN Kopran ₹281.55 1,361 54.5 700 25 8.7% 3.6% -96.0% -97.6% 13.9% -10.0%
❓ Frequently asked questions
What was Innova Captab Limited's revenue in Q1 FY27?
Innova Captab Limited reported revenue of ₹400 crore for the quarter ended June 2026 (Q1 FY27), up 39.5% from ₹287 crore in the same quarter last year, and up 11.8% sequentially over the March 2026 quarter.
What was Innova Captab Limited's net profit in Q1 FY27?
Net profit rose 58.0% year-on-year to ₹32 crore, from ₹20 crore. Earnings per share (EPS) came in at ₹5.60.
What is INNOVACAP's market capitalisation and P/E ratio?
At the current price of ₹1,019.80, INNOVACAP has a market capitalisation of ₹5,836 crore and a trailing P/E of about 61.1.
Who owns Innova Captab Limited? (shareholding pattern)
As of Sep 2026, promoters held 50.90%, foreign institutional investors (FIIs) 0.84%, domestic institutional investors (DIIs) 19.16%, public shareholders 29.09% of Innova Captab Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI